Kettering Health Now Offering Advanced Imaging to Detect Coronary Artery Disease
September 5, 2025
With coronary artery disease being the most common form of heart disease, early detection is important. New cutting-edge technologies at Kettering Health can help improve this, with their pioneering injectable radiopharmaceutical imaging agent, Flyrcado. Also known as flurpiridaz F-18, this FDA approved technology was made to assess the heart’s function under stress, offering superior diagnostic capabilities.